The identification of a small but significant subset of patients still targetable with anti-HER2 inhibitors when affected by triple negative breast carcinoma-Reference-Cited by-同舟云学术

The identification of a small but significant subset of patients still targetable with anti-HER2 inhibitors when affected by triple negative breast carcinoma

Published:2013-07-28 Issue:9 Volume:139 Page:1563-1568
ISSN:0171-5216
Container-title:Journal of Cancer Research and Clinical Oncology
language:en
Short-container-title:J Cancer Res Clin Oncol

Author:

Brunello Eleonora,Bogina Giuseppe,Bria Emilio,Vergine Marco,Zamboni Giuseppe,Pedron Serena,Daniele Isabella,Furlanetto Jenny,Carbognin Luisa,Marconi Marcella,Manfrin Erminia,Ibrahim Merdol,Miller Keith,Tortora Giampaolo,Molino Annamaria,Jasani Bharat,Beccari Serena,Bonetti Franco,Chilosi Marco,Martignoni Guido,Brunelli Matteo

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00432-013-1479-0.pdf

Reference22 articles.

1. Badve S, Dabbs DJ, Schnitt SJ, Baehner FL, Decker T et al (2011) Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. Mod Pathol 24:157–167

2. Bartlett JM, Ibrahim M, Jasani B, Morgan JM, Ellis I et al (2009) External quality assurance of HER2 FISH and ISH testing: 3 years of the UK national external quality assurance scheme. Am J Clin Pathol 131:106–111

3. Bartlett JM, Starczynski J, Atkey N, Kay E, O’Grady A et al (2011) HER2 testing in the UK: recommendations for breast and gastric in situ hybridisation methods. J Clin Pathol 64:649–653

4. Bloom KJ, Cote RJ (2011) Counterpoint: both immunohistochemistry and fluorescence in situ hybridization play important roles for HER2 evaluation. Clin Chem 57:983–985

5. Brunelli M, Manfrin E, Martignoni G, Bersani S, Remo A et al (2008) HER-2/neu assessment in breast cancer using the original FDA and new ASCO/CAP guideline recommendations: impact on selecting patients for herceptin therapy. Am J Clin Pathol 129:907–911

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Volume change rate before and after neoadjuvant systemic therapy of breast cancer is an efficacious evaluation index to predict pathological complete response;Frontiers in Oncology;2023-02-06

2. FISH testing of HER2 immunohistochemistry 1+ invasive breast cancer with unfavorable characteristics;Oncology Letters;2016-09-13

3. Biomarker Testing for Breast, Lung, and Gastroesophageal Cancers at NCI Designated Cancer Centers;JNCI: Journal of the National Cancer Institute;2014-09-12

4. Impact of HER2 copy number in IHC2+/FISH-amplified breast cancer on outcome of adjuvant trastuzumab treatment in a large UK cancer network;British Journal of Cancer;2014-04